Stockscreener 앱 받기
0.8909
3.87%
-0.0359
전일 마감가:
$0.9268
열려 있는:
$0.91
하루 거래량:
1.17M
Relative Volume:
0.47
시가총액:
$87.30M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+9.89%
1개월 성능:
+30.44%
6개월 성능:
-82.97%
1년 성능:
-75.25%
1일 변동 폭
$0.8523
$0.9181
1주일 범위
$0.8163
$0.9352
52주 변동 폭
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8909 | 90.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Aug Summary: Does aTyr Pharma Inc have pricing powerJuly 2025 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Market Outlook: Does aTyr Pharma Inc have pricing powerJuly 2025 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: aTyr Pharma (ATYR), Pfizer (PFE) and Bicycle Therapeutics (BCYC) - The Globe and Mail
Atyr Pharma CFO Broadfoot sells $1.5k in stock - Investing.com
Atyr Pharma CEO Shukla sells $3.6k in stock By Investing.com - Investing.com Nigeria
Atyr Pharma CEO Shukla sells $3.6k in stock - Investing.com UK
Atyr Pharma CFO Broadfoot sells $1.5k in stock By Investing.com - Investing.com South Africa
aTyr Pharma general counsel sells $1091 in stock By Investing.com - Investing.com UK
aTyr Pharma general counsel sells $1091 in stock - Investing.com
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting - Investing.com Nigeria
aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ) - Seeking Alpha
Atyr Pharma announces scheduling of FDA type C meeting to discuss efzofitimod program in pulmonary sarcoidosis - marketscreener.com
aTyr Pharma (ATYR) Prepares for Key FDA Meeting on Efzofitimod - GuruFocus
aTyr Pharma Schedules FDA Meeting to Discuss Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis - Quiver Quantitative
ATyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - marketscreener.com
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis - GlobeNewswire
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Federated Hermes Inc. Sells 4,122,163 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat
Short Interest in aTyr Pharma, Inc. (NASDAQ:ATYR) Drops By 14.7% - MarketBeat
Aug Action: What is aTyr Pharma Inc.’s TAM (Total Addressable Market)2025 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Is aTyr Pharma Inc. stock forming a triangle patternJuly 2025 Catalysts & Safe Capital Preservation Plans - Mfd.ru
Is aTyr Pharma Inc backed by strong institutional buyingJuly 2025 WrapUp & Reliable Intraday Trade Plans - baoquankhu1.vn
Aug Update: Does aTyr Pharma Inc. have pricing powerMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
aTyr Pharma, Inc. (NASDAQ:ATYR) Sees Significant Drop in Short Interest - MarketBeat
Published on: 2026-01-18 01:23:30 - baoquankhu1.vn
Volume Recap: What drives aTyr Pharma Incs stock priceWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How aTyr Pharma Inc. stock benefits from tech adoptionMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Will aTyr Pharma Inc. stock outperform growth indexesTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 Summary & Long-Term Growth Plans - ulpravda.ru
Aug Chart Watch: How aTyr Pharma Inc. stock benefits from tech adoptionWeekly Stock Recap & Intraday High Probability Alerts - ulpravda.ru
Can aTyr Pharma Inc. (471A) stock sustain breakout momentumDay Trade & Safe Capital Allocation Plans - ulpravda.ru
Aug EndMonth: Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
How strong is aTyr Pharma Inc. stock revenue growthPortfolio Return Report & Low Risk Investment Opportunities - ulpravda.ru
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a 483% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
aTyr Pharma (NASDAQ:ATYR) Stock Price Up 3.1%Still a Buy? - MarketBeat
Will aTyr Pharma Inc. stock attract ESG investorsStock Watchlist Updates & Exceptional Trading Strategies - ulpravda.ru
aTyr Pharma, Inc.Common Stock (NQ: ATYR - FinancialContent
Will aTyr Pharma Inc. (471A) stock beat Nasdaq index returns2026 world cup usa national team quarterfinals playmakers high defensive line expert forecast preview - Улправда
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR)Join by December 8, 2025Contact Levi & Korsinsky - The National Law Review
Is aTyr Pharma Inc. stock affected by interest rate hikesJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - Улправда
How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Buyback Activity & Fast Momentum Stock Entry Tips - Улправда
ATyr Pharma, Inc.(NasdaqCM:ATYR) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will aTyr Pharma Inc. stock remain a Wall Street favorite2025 Top Gainers & Technical Confirmation Alerts - Улправда
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):